Cover Image
市場調查報告書

SYNIMMUNE GmbH:產品平台分析

SYNIMMUNE GmbH - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319995
出版日期 內容資訊 英文 19 Pages
訂單完成後即時交付
價格
Back to Top
SYNIMMUNE GmbH:產品平台分析 SYNIMMUNE GmbH - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 19 Pages
簡介

SYNIMMUNE GmbH 是致力於造血器惡性腫瘤和固態惡性腫瘤的免疫療法上使用的單株抗體及雙特異性抗體的開發的生物科技企業。該公司的產品以Rituxan和Herceptin這個商品名廣為普及。

本報告提供SYNIMMUNE GmbH的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

SYNIMMUNE GmbH的基本資料

  • SYNIMMUNE GmbH概要
  • 主要資訊
  • 企業資料

SYNIMMUNE GmbH:R&D概要

  • 主要的治療範圍

SYNIMMUNE GmbH:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

SYNIMMUNE GmbH:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

SYNIMMUNE GmbH:藥物簡介

  • 4G8-SDIEM
  • K-ro8
  • NF-CU

SYNIMMUNE GmbH:開發平台分析

  • 各標靶
  • 各分子類型
  • 各作用機制

SYNIMMUNE GmbH:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07790CDB

Summary

Global Markets Direct's, 'SYNIMMUNE GmbH - Product Pipeline Review - 2015', provides an overview of the SYNIMMUNE GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SYNIMMUNE GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of SYNIMMUNE GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of SYNIMMUNE GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the SYNIMMUNE GmbH's pipeline products

Reasons to buy

  • Evaluate SYNIMMUNE GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of SYNIMMUNE GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the SYNIMMUNE GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of SYNIMMUNE GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of SYNIMMUNE GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of SYNIMMUNE GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • SYNIMMUNE GmbH Snapshot
    • SYNIMMUNE GmbH Overview
    • Key Information
    • Key Facts
  • SYNIMMUNE GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • SYNIMMUNE GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • SYNIMMUNE GmbH - Pipeline Products Glance
    • SYNIMMUNE GmbH - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • SYNIMMUNE GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • SYNIMMUNE GmbH - Drug Profiles
    • 4G8-SDIEM
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Kro-8
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NF-CU
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • SYNIMMUNE GmbH - Pipeline Analysis
  • SYNIMMUNE GmbH - Pipeline Products by Target
  • SYNIMMUNE GmbH - Pipeline Products by Molecule Type
  • SYNIMMUNE GmbH - Pipeline Products by Mechanism of Action
  • SYNIMMUNE GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • SYNIMMUNE GmbH, Key Information
  • SYNIMMUNE GmbH, Key Facts
  • SYNIMMUNE GmbH - Pipeline by Indication, 2015
  • SYNIMMUNE GmbH - Pipeline by Stage of Development, 2015
  • SYNIMMUNE GmbH - Monotherapy Products in Pipeline, 2015
  • SYNIMMUNE GmbH - Phase I, 2015
  • SYNIMMUNE GmbH - Preclinical, 2015
  • SYNIMMUNE GmbH - Pipeline by Target, 2015
  • SYNIMMUNE GmbH - Pipeline by Molecule Type, 2015
  • SYNIMMUNE GmbH - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • SYNIMMUNE GmbH - Pipeline by Top 10 Indication, 2015
  • SYNIMMUNE GmbH - Pipeline by Stage of Development, 2015
  • SYNIMMUNE GmbH - Monotherapy Products in Pipeline, 2015
  • SYNIMMUNE GmbH - Pipeline by Top 10 Molecule Type, 2015
Back to Top